Your session is about to expire
← Back to Search
Behavioural Intervention
Transcranial Electromagnetic Treatment Against Alzheimer's Disease
N/A
Waitlist Available
Led By Amanda Smith, MD
Research Sponsored by NeuroEM Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up changes from baseline mmse score at two and four months into treatment
Awards & highlights
No Placebo-Only Group
Summary
This trial extends a previous study to see if using TEMT for a longer time can further improve or stabilize cognitive functions in Alzheimer's patients. TEMT uses electromagnetic waves on the head, which may help clear harmful brain proteins and improve memory and thinking skills. This treatment has shown promise in reversing cognitive impairment in Alzheimer's patients in previous studies.
Eligible Conditions
- Alzheimer's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline adas-cog at two and four months into treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline adas-cog at two and four months into treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
ADAS-cog score
Secondary study objectives
Adverse Event Assessment
Clock draw score
Digit span score
+5 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TEMT AdministrationExperimental Treatment1 Intervention
Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MemorEM 1000
2017
N/A
~10
Find a Location
Who is running the clinical trial?
NeuroEM Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
14 Total Patients Enrolled
University of South Florida Health / Byrd Alzheimer's InstituteUNKNOWN
Amanda Smith, MDPrincipal InvestigatorUniversity of South Florida Health / Byrd Alzheimer's Institute
2 Previous Clinical Trials
38 Total Patients Enrolled